Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $65.7 million.

  • Beam Therapeutics' Cash from Investing Activities rose 16583.12% to $65.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.6 million, marking a year-over-year decrease of 16603.82%. This contributed to the annual value of $185.0 million for FY2024, which is 15752.64% up from last year.
  • Beam Therapeutics' Cash from Investing Activities amounted to $65.7 million in Q3 2025, which was up 16583.12% from -$170.4 million recorded in Q2 2025.
  • Beam Therapeutics' Cash from Investing Activities' 5-year high stood at $126.3 million during Q4 2024, with a 5-year trough of -$537.3 million in Q1 2022.
  • In the last 5 years, Beam Therapeutics' Cash from Investing Activities had a median value of -$10.2 million in 2023 and averaged -$38.3 million.
  • In the last 5 years, Beam Therapeutics' Cash from Investing Activities tumbled by 318684.63% in 2023 and then surged by 34142.72% in 2024.
  • Over the past 5 years, Beam Therapeutics' Cash from Investing Activities (Quarter) stood at -$77.5 million in 2021, then surged by 246.38% to $113.4 million in 2022, then dropped by 13.52% to $98.1 million in 2023, then increased by 28.73% to $126.3 million in 2024, then plummeted by 48.01% to $65.7 million in 2025.
  • Its Cash from Investing Activities was $65.7 million in Q3 2025, compared to -$170.4 million in Q2 2025 and -$125.1 million in Q1 2025.